Event
Shaping the Biotech Act: lunch discussion in the European Parliament
On 22 April 2026, the Co-Chairs of the MEP Group for Transformative Therapies, MEPs Stine Bosse (Renew Europe, Denmark), Billy Kelleher (Renew Europe, Ireland), and Tomislav Sokol (European People’s Party, Croatia), co-hosted a roundtable with the TRANSFORM Alliance. The discussion focused on the Biotech Act I and its implications for Advanced Therapy Medicinal Products (ATMPs).
The meeting was structured around three breakout tables addressing different aspects of the Biotech Act I. The discussions brought together key representatives from the European Institutions, alongside stakeholders from the industry, academia, healthcare professionals and patient organisations.
Taking place at a pivotal moment for shaping the real-world impact of the Biotech Act, the initiative aimed to foster cross-sector dialogue on key aspects of the legislation. Its objective was to define priority axes and actionable recommendations for the upcoming negotiations, while ensuring that stakeholders’ perspectives are effectively reflected in the policy-making process.
Through the different perspectives shared, a clear and cross-cutting message emerged: the EU’s main challenge is not to design new, nor more flexible regulatory European frameworks, but most importantly to ensure their effective implementation on the ground. This requires enhanced coordination and cooperation between the 27 Member States, as well as a stronger EU support to strengthen the latter’s capacity to both invest, innovate, and overall build a truly competitive and equitable health ecosystem capable of delivering safe, high-quality, and tailored treatments to patients in Europe.